BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
Pharma & GLP-1 · 24 May 2026
CHMP Backs Both High-Dose Wegovy HD and Oral Semaglutide for EU Approval — What the Twin Opinions Mean for the Research Landscape
On 22 May 2026, the EMA's Committee for Medicinal Products for Human Use issued positive opinions recommending EU marketing authorisation for both Wegovy HD 7.2 mg in a single-dose pen and the oral Wegovy pill (semaglutide 25 mg). The twin rulings advance semaglutide into new dosing and delivery territory across Europe — with distinct implications for UK regulatory timelines, research procurement, and the purity concerns that continue to surround the grey-market semaglutide supply chain.
Read briefing →
Research Pipeline
GHK-Cu: The Copper Tripeptide Facing Its Second Regulatory Wave — What Research Labs Need to Know
GHK-Cu (copper tripeptide-1) has one of the stronger mechanistic evidence bases among research peptides, spanning wound healing, collagen remodelling, and genomic modulation of over a thousand genes. Following the FDA's April 2026 Federal Register notice, it now sits in the second wave of PCAC review, scheduled before February 2027. This briefing covers its biochemistry, the state of the clinical evidence, and what the split regulatory picture means for UK procurement teams.
24 May 2026
Pharma & GLP-1
EASO's 2026 Living Algorithm Separates Tirzepatide and Semaglutide by Indication — With MASH Data Sharpening the Divide
The European Association for the Study of Obesity has published its first update to its GLP-1 pharmacotherapy framework, drawing a clearer evidence-based distinction between tirzepatide and semaglutide. Tirzepatide now sits above semaglutide for total body weight loss, while semaglutide is the only agent currently supported for liver fibrosis improvement — a split with direct implications for research strategy as Novo Nordisk advances its MASH programme into EASL 2026.
21 May 2026
Reputational Risks
GLP-1 Popularity Is Fuelling Unverified Peptide Promotion Online — and Raising Purity Concerns for Research Procurement
The clinical success of injectable GLP-1 drugs has triggered a surge of social media promotion for a much broader range of unverified peptides, with physicians warning that many products contain minimal active ingredient or outright contaminants. For research-procurement professionals, the same market dynamics create real supply-chain risks that standard vendor screening must address.
19 May 2026
Research Pipeline
TRIUMPH-4 read-out: retatrutide hits 28.7% weight loss but a new dysesthesia signal complicates the path to filing
Eli Lilly's triple-agonist retatrutide produced the highest weight-loss percentage ever recorded in a Phase 3 obesity trial in TRIUMPH-4, but a new dysesthesia signal — not seen in Phase 2 — affected one in five patients on the top dose. With seven further Phase 3 read-outs scheduled across 2026, the next nine months will determine whether retatrutide rewrites the GLP-1 competitive map or carries a safety footnote into the label.
18 May 2026
Industry & Community
Macrocyclic Peptides Draw Wave of Institutional Capital in 2026 as Big Pharma Targets "Undruggable" Biology
A cluster of deals in early 2026 has placed macrocyclic peptides at the centre of pharmaceutical dealmaking, with Syneron Bio closing a $150 million Series B, Novartis committing up to $1.8 billion to Unnatural Products, and AstraZeneca holding a strategic stake in the macrocycle space. For research-procurement teams, the surge signals where institutional confidence in the peptide modality is moving.
15 May 2026
Research Pipeline
Foundayo (Orforglipron) Sustains Most Injectable GLP-1 Weight Loss in Phase 3b Switch Trial, New Data Show
A Phase 3b trial published in Nature Medicine on 12 May 2026 shows that patients who switched from injectable tirzepatide or semaglutide to once-daily oral orforglipron (Foundayo) retained 75–79% of their prior weight loss over 52 weeks. The data, presented simultaneously at the European Congress on Obesity, add clinical depth to an already-approved drug and sharpen the debate over whether oral small-molecule GLP-1 agonists can serve as maintenance therapy after injectable induction.
15 May 2026
Regulatory & Policy
FDA Proposes to Close Large-Scale GLP-1 Compounding for Good, Targeting the 503B Outsourcing Pathway
The FDA has proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these GLP-1 drugs from bulk substances. The move would close the last remaining large-scale compounding pathway, with implications for API supply, research procurement, and the broader peptide market.
09 May 2026
Research Pipeline
Oral Small-Molecule GLP-1 Drugs Reach Deep Brain Reward Circuits, Pointing Towards Addiction Research Applications
A Nature study published 6 May 2026 found that oral small-molecule GLP-1 receptor agonists, including orforglipron and danuglipron, suppress hedonic feeding in mice by modulating a reward circuit in the central amygdala — a mechanism distinct from the hypothalamic appetite pathways activated by peptide-based GLP-1 drugs. The findings add mechanistic weight to a growing body of evidence linking GLP-1 pharmacology to reduced substance use disorder risk.
08 May 2026
Research Pipeline
MOTS-c: The Mitochondrial Peptide Generating Research Interest in Metabolic Disease and Ageing
MOTS-c is a 16-amino-acid peptide encoded not by the nuclear genome but by the mitochondrial genome, placing it in a distinct class from most research peptides. Growing preclinical data point to roles in glucose metabolism, insulin sensitivity, muscle preservation and β-cell protection, though no approved therapeutic use exists and regulatory status in both the US and UK remains firmly research-only.
08 May 2026
Regulatory & Policy
FDA Tightens GLP-1 Compounding Rules While Scheduling First Formal Review of BPC-157, TB-500 and Five Other Peptides
The FDA issued a proposal on 30 April 2026 to permanently exclude semaglutide, tirzepatide and liraglutide from the 503B bulk compounding list, citing no clinical need. Separately, the agency has confirmed a two-day Pharmacy Compounding Advisory Committee meeting on 23–24 July 2026 to evaluate seven peptides — including BPC-157, TB-500 and Semax — for potential inclusion on the 503A Bulks List, the first formal step toward regulated compounding access since twelve substances were removed from…
07 May 2026
Pharma & GLP-1
Wegovy oral pill claims early US lead over Lilly's Foundayo as Novo Nordisk Q1 results approach
Novo Nordisk's oral semaglutide pill (FDA-approved December 2025) and Eli Lilly's orforglipron (Foundayo, approved 1 April 2026) are now competing head-to-head in the US oral GLP-1 market. Cross-trial data favours Wegovy on weight loss; Foundayo has a usability edge. UK launch timing is unclear pending MHRA review.
05 May 2026